Bebtelovimab COVID-19 studies. Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BQ.1.1 [Planas]. Monoclonal antibody use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape [Choudhary].
Recent:Sridhara Molina Kip.
Bebtelovimab has been officially adopted
in 1 country.
Submit updates/corrections .
Apr 28 |
et al., PLOS ONE, doi:10.1371/journal.pone.0279326 | Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era |
| 86% lower mortality [p=0.25], 25% lower combined mortality/hospitalization [p=0.31], and 11% lower hospitalization [p=0.78]. PSM retrospective 19,778 high-risk outpatients in the USA, showing no significant difference in outcomes with bebtelovimab treatment. | ||
Apr 16 |
et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2023.04.396 | Real-World Evaluation of Bebtelovimab Effectiveness During the Period of COVID-19 Omicron Variants including BA.4/BA.5 |
| 57% lower mortality [p=0.14], 59% lower ICU admission [p=0.05], 56% lower hospitalization [p<0.0001], and 33% higher progression [p=0.001]. Retrospective 3,739 patients treated with bebteloviman in the USA and matched controls, showing lower mortality and hospitalization with treatment, but higher emergency department visits. | ||
Apr 4 |
et al., Annals of Internal Medicine, doi:10.7326/M22-1286 | Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 |
| 20% lower combined mortality/hospitalization [p=0.65]. Retrospective 2,571 patients treated with mAbs in the USA, and 5,135 control patients, showing lower combined mortality/hospitalization for bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, sotrovimab, and bebtelovimab, with s.. | ||
Nov 17 |
et al., bioRxiv, doi:10.1101/2022.11.17.516888 (Preprint) (In Vitro) | Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies |
| In Vitro study suggesting a lack of efficacy for bebtelovimab with BQ.1.1. | ||
Oct 27 |
et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac565 | Bebtelovimab for high-risk outpatients with early COVID-19 in a large US health system |
| 86% lower mortality [p=0.25], 43% lower combined mortality/hospitalization [p=0.14], and 29% lower hospitalization [p=0.53]. Retrospective 377 outpatients in the USA and matched controls, showing lower hospitalization/mortality with bebtelovimab treatment, without statistical significance. Notably, none of the patients that died in the control group were hospit.. | ||
Feb 12 |
(Preprint) | A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness |
| 36% improved viral clearance [p=0.07]. RCT with 127 bamlanivimab, etesevimab, and bebtelovimab patients, 125 bebtelovimab patients, and 128 control patients, showing no significant differences in hospitalization and mortality. Viral clearance was improved although not statisti.. | ||
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.